Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs iShares China Large-Cap ETF (FXI) Price & Performance

DexCom, Inc.Trade
iShares China Large-Cap ETFTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs iShares China Large-Cap ETF — how do they compare? DexCom, Inc. trades at $90.13 (market cap $33.79B), while iShares China Large-Cap ETF trades at $35.21. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.

DXCMFXI
Market Cap
$33.79B
Sector
Health
52-Week High
$89.53$41.75
52-Week Low
$54.84$31.59
Enterprise Value
$33.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

iShares China Large-Cap ETF

FXI, the iShares China Large-Cap ETF, trades at $35.26, down 3.37% on the day, reflecting recent pressure on Chinese equities. Technical indicators show a bullish moving average signal but neutral oscillators, with key resistance at $37. Recent news highlights China's export strength and state-backed economic support, though geopolitical tensions and U.S. restrictions pose headwinds. The ETF offers exposure to China's financial and industrial giants, with a dividend scheduled for June 2026.

The outlook for FXI is mixed; bullish technical trends and China's policy support may drive gains, but risks include U.S.-China tensions and domestic economic volatility. Investors should weigh diversification benefits against regulatory and macroeconomic uncertainties, with Wall Street sentiment cautious amid fluctuating analyst views.

Returns comparison

Trailing returns across standard periods

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI